AR006583A1 - Una composición farmacéutica - Google Patents

Una composición farmacéutica

Info

Publication number
AR006583A1
AR006583A1 ARP970101419A ARP970101419A AR006583A1 AR 006583 A1 AR006583 A1 AR 006583A1 AR P970101419 A ARP970101419 A AR P970101419A AR P970101419 A ARP970101419 A AR P970101419A AR 006583 A1 AR006583 A1 AR 006583A1
Authority
AR
Argentina
Prior art keywords
composition
pharmaceutical composition
salt
mycophenolate
immunosuppression
Prior art date
Application number
ARP970101419A
Other languages
English (en)
Inventor
Ching Pong Mak
Barbara Harberlin
Armin Meinzer
Jacky Vonderscher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR006583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR006583A1 publication Critical patent/AR006583A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición farmacéutica que comprende una sal de mcofenolato, estando la composición adaptada para liberar micofenolato en la parte superior del tractointestinal. Particulamente dicha composición comprende una sal de micofenolato farmacéuticamente aceptable con revestimiento entérico. También proporciona eluso de dicha composición farmacéutica en la preparación de un medicamento para inmunosupresión, particularmente para la prevención de rechazo de trasplante dehaloinjerto o xenoinjerto,na tivo o transgénico de órgano, tejido o de células; para el tratamiento o prevención de enfermedades mediadas por el sistema inmuney/o enfermedades inflamatorias. Asimismo proporciona un método para inmunosuprimir a un sujeto, el cualcomp rende administrar una cantidadterapéuticamente efectiva de dicha sal de micofenolato farmacéuticamente aceptable, con revestimiento entérico o dicha composición a un sujeto ennecesidad de inmunosupresión, opcionalmente con laadministración si multánea o separada de otro inmunosupresor.
ARP970101419A 1996-04-12 1997-04-10 Una composición farmacéutica AR006583A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
AR006583A1 true AR006583A1 (es) 1999-09-08

Family

ID=26309105

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101419A AR006583A1 (es) 1996-04-12 1997-04-10 Una composición farmacéutica
ARP070100839A AR059693A2 (es) 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070100839A AR059693A2 (es) 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso

Country Status (34)

Country Link
US (3) US6025391A (es)
EP (2) EP0892640B1 (es)
JP (2) JP3779732B2 (es)
CN (1) CN1104238C (es)
AR (2) AR006583A1 (es)
AT (2) ATE259228T1 (es)
AU (1) AU725388B2 (es)
BE (1) BE1010963A3 (es)
BR (1) BR9708624A (es)
CO (1) CO4900024A1 (es)
CY (1) CY2243B1 (es)
CZ (1) CZ291811B6 (es)
DE (4) DE69727559T2 (es)
DK (1) DK0892640T3 (es)
ES (2) ES2216141T3 (es)
FR (1) FR2747920B1 (es)
GB (1) GB2326339B (es)
GR (1) GR1002893B (es)
HK (2) HK1016490A1 (es)
HU (1) HU224919B1 (es)
ID (1) ID18663A (es)
IE (1) IE970267A1 (es)
IL (1) IL126431A (es)
IT (1) IT1297045B1 (es)
LU (1) LU91094I2 (es)
MY (1) MY119049A (es)
NL (1) NL300157I2 (es)
NO (2) NO322891B1 (es)
NZ (1) NZ332117A (es)
PT (1) PT892640E (es)
RU (2) RU2203659C2 (es)
TR (1) TR199802056T2 (es)
TW (1) TW457098B (es)
WO (1) WO1997038689A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60044717D1 (de) 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
CA2461730C (en) * 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
MXPA06005659A (es) * 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
US7358247B2 (en) 2004-04-27 2008-04-15 TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság Mycophenolate mofetil impurity
JP2008506783A (ja) 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸ナトリウムの結晶形の調製方法
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
BRPI0614914A2 (pt) 2005-07-29 2011-04-19 Solvay Pharm Gmbh processos para a fabricação de pó de pancreatina esterilizada
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
CA2640283A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (mpa)
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2008015797A (es) * 2007-04-11 2009-03-06 Teva Gyogyszergyar Zartkoeruen Metodo para reducir el nivel de impurezas en la fermentacion del acido micofenolico.
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
ES2683355T3 (es) 2013-03-14 2018-09-26 Alkermes Pharma Ireland Limited Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
EP3091974B1 (en) 2014-01-06 2020-04-01 Shield TX (UK) Limited Dosage regimen of ferric trimaltol
NZ723269A (en) 2014-02-24 2017-04-28 Alkermes Pharma Ireland Ltd Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
BR112019019003A2 (pt) * 2017-03-13 2020-04-14 Okava Pharmaceuticals Inc métodos e composições para dispensação de agentes ativos de ácidos micofenólicos a mamíferos não humanos
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (es) * 1972-02-24 1980-11-04
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
AU6826194A (en) * 1993-05-06 1994-12-12 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
PT892640E (pt) 2004-06-30
WO1997038689A3 (en) 1997-12-04
DE122004000038I1 (de) 2006-01-26
DK0892640T3 (da) 2004-05-10
GB2326339B (en) 2000-04-19
ES2178510A1 (es) 2002-12-16
JP2006063086A (ja) 2006-03-09
CN1104238C (zh) 2003-04-02
AR059693A2 (es) 2008-04-23
LU91094I2 (fr) 2004-10-11
GR1002893B (el) 1998-04-10
MY119049A (en) 2005-03-31
NL300157I1 (nl) 2004-10-01
FR2747920B1 (fr) 1999-12-31
IT1297045B1 (it) 1999-08-03
IL126431A0 (en) 1999-08-17
US6306900B1 (en) 2001-10-23
AT408415B (de) 2001-11-26
NO2007004I2 (no) 2009-10-19
RU2615397C2 (ru) 2017-04-04
GB9821304D0 (en) 1998-11-25
ITRM970207A1 (it) 1998-10-11
ID18663A (id) 1998-04-30
US6025391A (en) 2000-02-15
DE69727559T2 (de) 2004-12-16
EP1221316A1 (en) 2002-07-10
ATA905997A (de) 2001-04-15
IE970267A1 (en) 1997-10-22
CZ291811B6 (cs) 2003-06-18
ATE259228T1 (de) 2004-02-15
HUP9903373A3 (en) 2001-05-28
EP0892640B1 (en) 2004-02-11
FR2747920A1 (fr) 1997-10-31
EP0892640A2 (en) 1999-01-27
HUP9903373A2 (hu) 2001-04-28
CO4900024A1 (es) 2000-03-27
GB2326339A (en) 1998-12-23
NO2007004I1 (no) 2007-04-16
HU224919B1 (en) 2006-04-28
AU2384397A (en) 1997-11-07
NO322891B1 (no) 2006-12-18
BE1010963A3 (fr) 1999-03-02
RU2203659C2 (ru) 2003-05-10
TR199802056T2 (xx) 1999-02-22
JP3779732B2 (ja) 2006-05-31
HK1051484A1 (zh) 2003-08-08
TW457098B (en) 2001-10-01
DE19781690D2 (de) 1999-04-08
DE122004000038I2 (de) 2006-04-27
AU725388B2 (en) 2000-10-12
JP2000503665A (ja) 2000-03-28
CN1215991A (zh) 1999-05-05
DE69727559D1 (de) 2004-03-18
NL300157I2 (nl) 2004-12-01
NO984728D0 (no) 1998-10-09
ES2178510B1 (es) 2004-08-16
ES2216141T3 (es) 2004-10-16
HK1016490A1 (en) 1999-11-05
CY2243B1 (en) 2003-07-04
NO984728L (no) 1998-12-02
IL126431A (en) 2005-03-20
NZ332117A (en) 2000-04-28
US6172107B1 (en) 2001-01-09
WO1997038689A2 (en) 1997-10-23
CZ326798A3 (cs) 1999-01-13
BR9708624A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
AR006583A1 (es) Una composición farmacéutica
Grant et al. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
RU98120360A (ru) Фармацевтические композиции на основе микофенолята с энтеросолюбильным покрытием
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
CO4750822A1 (es) Formulaciones farmaceuticas tada para la administracion en el tracto gastrointestinal y procesos para elaborar las mismas
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
Pintér et al. Increased survival and reinnervation of cervical motoneurons by riluzole after avulsion of the C7 ventral root
Karussis et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation
NO975334D0 (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
GB0008269D0 (en) Combination chemotherapy
JP2002527401A5 (es)
CA2093513A1 (en) Methods and compositions for suppressing allograft rejection in mammals
LU88684I2 (fr) Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet )
Siemionow et al. Advances in composite tissue allograft transplantation as related to the hand and upper extremity
US20180344808A1 (en) Haptoglobin derivative for treatment of sepsis and acetaminophen-induced liver damage
JP2013028623A (ja) 虚血性再灌流傷害または多臓器不全の治療または予防方法
CA2505141A1 (en) Chaperonin 10 immunosuppression
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
BR0114642A (pt) Prevenção de doenças através da reativação do timo
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.
Brenner et al. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior

Legal Events

Date Code Title Description
FG Grant, registration